Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group

PURPOSE: To evaluate the efficacy and tolerability of bortezomib in combination with doxorubicin in patients with advanced hepatocellular carcinoma, and to correlate pharmaco-dynamic markers of proteasome inhibition with response and survival. Experimental Design This phase II, open-label, multi-cen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ciombor, Kristen K., Feng, Yang, Benson, Al Bowen, Su, Yingjun, Horton, Linda, Short, Sarah P., Kauh, John Sae Wook, Staley, Charles, Mulcahy, Mary, Powell, Mark, Amiri, Katayoun I., Richmond, Ann, Berlin, Jordan
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4171216/
https://ncbi.nlm.nih.gov/pubmed/24890858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0111-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados